DIAGNOSTIC REPORT

MC-5875

agilus diagnostics
Dr. Phadke Labs

PATIENT NAME : SHAKEEL AHMED **REF. DOCTOR :** SELF

CODE/NAME & ADDRESS : CS00008327 MEDICARE DIAGNOSTIC CENTRE(MAHIM) 129 GOVERNOR LANE NEAR VAIBHAV APT OPP. GHAZIRESTAURANT, MAIN ROAD, MAHIM (E) MUMBAI 400017 7718982967 9702341601	ACCESSION NO : **5047XH002706** PATIENT ID : SHAKM0208585047 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :66 Years Male DRAWN : RECEIVED : 02/08/2024 14:26:59 REPORTED :03/08/2024 09:26:35

Test Report Status **Final**	Results	Biological Reference Interval	Units

SPECIALISED CHEMISTRY - TUMOR MARKER

CARCINO EMBRYONIC ANTIGEN, SERUM

CARCINO EMBRYONIC ANTIGEN	**1279.2 High**	0 - 5	ng/mL

METHOD : CMIA

Comments

Rechecked.
Kindly Correlate Clinically And With Treatment History.
Advice follow up testing.

Interpretation(s)
CARCINO EMBRYONIC ANTIGEN, SERUM-Carcinoembryonic antigen (CEA) is a glycoprotein and belongs to a group of tumor markers referred to as oncofetal proteins. Increased serum CEA levels have been detected in persons with primary colorectal cancer and in patients with other malignancies including cancers of the gastrointestinal tract, breast, lungs, ovaries, prostate, liver and pancreas. Elevated serum CEA levels have also been detected in patients with non-malignant disease, especially patients who are older or in smokers. CEA levels are not useful in screening the general population for undetected cancers. However, CEA levels provide important information about patient prognosis, recurrence of tumors after surgical removal and effectiveness of therapy. Serial CEA levels are useful in monitoring the course of disease. CEA levels generally fall to normal or near normal levels within 1 to 4 months after surgical removal of cancerous tissue. A rise in CEA levels may be the first indication of recurrence and may precede physical signs and symptoms. Serial CEA levels are also useful in assessing the effectiveness of therapy or possible metastasis. CEA is a useful tool for monitoring and managing cancer therapy and provides the clinician with additional information about patient prognosis.The concentration of CEA in a given specimen, as determined by assays from different manufacturers, can vary due to differences in assay methods and reagent specificity. Values obtained with different assay method cannot be used interchangeably.Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous values may be observed.

CEA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations.Recommended follow up on same platform as patient result can vary due to differences in assay method and reagent specificity.

****End Of Report****
Please visit www.agilusdiagnostics.com for related Test Information for this accession

DR. SONAL PRIYA
CONSULTANT PATHOLOGIST

View Details View Report

PERFORMED AT :
Agilus Pathlabs Private Limited

Mahalakshmi Industrial Estate, Mahim WestMumbai - 400016
Tel : +91 22 48247247/022 68247247, **Fax :** CIN - U85I95DL1999PTC217659 **Web :** www.agilusdiagnostics.com

ULR No.504700007190872-5047

DIAGNOSTIC REPORT

MC-5875

agilus diagnostics
Dr. Phadke Labs

PATIENT NAME : SHAKEEL AHMED **REF. DOCTOR :** SELF

CODE/NAME & ADDRESS : CS00008327 MEDICARE DIAGNOSTIC CENTRE(MAHIM) 129 GOVERNOR LANE NEAR VAIBHAV APT OPP. GHAZIRESTAURANT, MAIN ROAD, MAHIM (E) MUMBAI 400017 7718982967 9702341601	ACCESSION NO : **5047XH002706** PATIENT ID : SHAKM0208585047 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :66 Years Male DRAWN : RECEIVED : 02/08/2024 14:26:59 REPORTED :03/08/2024 09:26:35

Test Report Status **Final**	Results	Biological Reference Interval	Units

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
   i. Specimen received is insufficient or inappropriate
   ii. Specimen quality is unsatisfactory
   iii. Incorrect specimen type
   iv. Discrepancy between identification on specimen container label and test requisition form
5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

.

Agilus Diagnostics Ltd
Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062

DR. SONAL PRIYA
CONSULTANT PATHOLOGIST

View Details View Report

PERFORMED AT :
Agilus Pathlabs Private Limited

Mahalakshmi Industrial Estate, Mahim WestMumbai - 400016
Tel : +91 22 48247247/022 68247247, **Fax :** CIN - U85I95DL1999PTC217659 **Web :** www.agilusdiagnostics.com

ULR No.504700007190872-5047